Press release
Cataract Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - CGeneTech (CGT 1507), Nacuity Pharma (NPI 002), and Plex Pharmaceuticals
As per DelveInsight's assessment, globally, several major pharma and biotech giants are actively working in the Cataract therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Cataract Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cataract Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Cataract Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Cataract Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cataract treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cataract market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Cataract pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as -
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various molecule types, such as -
- Oligonucleotide
- Peptide
- Small molecule
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Cataract Therapeutics Analysis
Globally, several major pharma and biotech giants are developing therapies for cataracts. Currently, Nacuity Pharmaceuticals is leading the therapeutics market with its Cataract drug candidates in the most advanced stage of clinical development.
Some of the Key Companies in the Cataract Therapeutics Market Include:
- Nacuity Pharmaceuticals
- CGeneTech
- Plex Pharmaceuticals
And Many More
Cataract Drugs Covered in the Report Include:
- CGT 1507: CGeneTech
- NPI 002: Nacuity Pharmaceuticals
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Cataract Current Treatment Patterns
4. Cataract - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cataract Late-Stage Products (Phase-III)
7. Cataract Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cataract Discontinued Products
13. Cataract Product Profiles
14. Cataract Key Companies
15. Cataract Key Products
16. Dormant and Discontinued Products
17. Cataract Unmet Needs
18. Cataract Future Perspectives
19. Cataract Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cataract Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - CGeneTech (CGT 1507), Nacuity Pharma (NPI 002), and Plex Pharmaceuticals here
News-ID: 2924517 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Cataract
Transformative Trends Impacting the Cataract Surgery Devices And Equipment Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Cataract Surgery Devices And Equipment Market Size By 2025?
The market size for cataract surgery devices and equipment has shown a consistent growth trend in recent years. It is projected to increase from $13.97 billion in 2024 to $14.52 billion in 2025, exhibiting a compound…
Cataract Pipeline: Emerging Non-Surgical Solutions and Leading Companies Shaping …
The therapeutic landscape for Cataract, the leading cause of blindness globally, is undergoing a paradigm shift as researchers and biopharmaceutical companies explore non-surgical and disease-modifying alternatives to conventional cataract extraction surgery. Advances in molecular biology, oxidative stress modulation, and crystallin protein stabilization have opened new avenues for pharmacological intervention. Companies like Nacuity Pharmaceuticals, CGeneTech, and Plex Pharmaceuticals are pioneering efforts to develop novel agents aimed at delaying, halting, or reversing…
Cataract Surgery Devices Market - Innovation Meets Precision: Elevate Cataract S …
Newark, New Castle, USA: The "Cataract Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cataract Surgery Devices Market: https://www.growthplusreports.com/report/cataract-surgery-devices-market/7846
This latest report researches the industry structure,…
Intraocular Lens Implants for Cataract Market is Driven by the Increasing Incide …
The proposed Intraocular Lens Implants for Cataract Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics.
The Intraocular Lens Implants for Cataract Market…
Potential Opportunities of Cataract Surgical Devices Market
The global cataract surgical devices market size is projected to reach USD 9.98 billion by the end of 2026. The high prevalence of cataract disorders will open up a huge potential for market growth. According to a report published by Fortune Business Insights, titled "Cataract Surgical Devices Market Size, Share & Industry Analysis, By Product Type (Phacoemulsification Systems, Femtosecond Laser, Intraocular Lenses, Ophthalmic Viscoelastic Devices & Other Consumables), By End-user…
Cataract Surgery Devices Market Opportunity Analysis, 2018-2026
Cataract surgery devices are used during the surgical procedures to treat cataract, which is an eye disorder that causes clouding of the lens leading to defects in vision. Cataract is one of the most widespread disease causing blindness and it reduces vision ability. Cataract is often encountered to develop slowly and affect either one or both the eyes.
Although cataract does not interfere with the eyesight in the early stages, it…
